

<b>LAST NAME : GIRAUDET</b>		<b>First name : Anne-Laure</b>		<b>Title : Dr</b>	
<b>Medical License number (N° RPPS) : 10001547958</b>			<b>Registration place : Rhône, France</b>		
CENTRE LEON BERARD 28 rue Laennec 69373 LYON cedex 08 - FRANCE			Department : Nuclear Medicine Telephone : +33 (0)469856001 / Fax : +33 (0)478782906 E-mail: AnneLaure.GIRAUDET@lyon.unicancer.fr		
<b>PROFESSIONAL EXPERIENCE</b>					
<b>Current position</b>				<b>Since</b>	
NUCLEAR MEDICINE PHYSICIAN				November 2012	
<b>Previous positions</b>					
From	To	Position	Institution	City	Country
2012	ONG	NUCLEAR MEDICINE PHYSICIAN HEAD OF THE RLT DEPARTMENT	Centre Léon Bérard	Lyon	France
2008	2012	NUCLEAR MEDICINE PHYSICIAN	René Huguenin-Curie	Saint-Cloud	France
2007	2008	fellowship	Peter Mac Callum	Melbourne	Australia
2005	2007	senior nuclear medicine physician	Gustave Roussy	Villejuif	France
2002	2006	Assistante hospitalo-universitaire	Cochin	Paris	France
1997	2002	Internship	AP-HP	Paris	France
<b>EDUCATION</b>					
Year	Degree		Institution	City	Country
2014	2018 PHD		EDISS, UCBL 1	Lyon	France
2010	2011 DIU endocrine tumors		Paris XI	Paris	France
2003	2004 MASTER radiobiology		Paris XI	Paris	France
2000	2001 certificate in biotechnologies and gene transfert		Paris VI	Paris	France
1998	1999 certificate in molecular biology and oncogenesis		Paris V	Paris	France
<b>OTHER TRAINING</b>					
Year	Degree		Institution	City	Country
2009	concours specialist of French cancer centers		René Huguenin-Curie	Saint Cloud	France
2004	2004 DESC oncology		AP-HP	Paris	France
2002	DES nuclear medicine		AP-HP	Paris	France
2002	Doctorat de médecine		AP-	Paris	France
2018	PHD		UCBL1	LYON	FRANCE
<b>GOOD CLINICAL PRATICE (GCP) TRAINING</b>					
Date of the last certificate : 21/dec/2022 Course provider : The Global Health Network					
<b>CLINICAL TRIALS EXPÉRIENCE : &gt; 25 NUCLEAR MEDICINE STUDIES INCLUDING 18 OF RLT (5 PI)</b>					
Participation in clinical trials of <i>Participation à des essais cliniques de</i> <input checked="" type="checkbox"/> phase I <input checked="" type="checkbox"/> phase II <input checked="" type="checkbox"/> phase III					
As <input checked="" type="checkbox"/> coordinating investigator <input checked="" type="checkbox"/> principal investigator <input checked="" type="checkbox"/> subinvestigator					
<i>En tant que</i> <i>investigateur coordonnateur</i> <i>investigateur principal</i> <i>investigateur</i>					
Brief summary ( <i>pathologies, therapeutic areas...</i> ) <i>Résumé succinct (pathologies, domaines thérapeutiques...)</i> :					
Thyroid cancer, endocrine tumors, prostate cancer, sarcoma, pediatric oncology, in relation with nuclear medicine mainly with radionuclide therapy.					
<b>PUBLICATIONS : INDICE H 17 ; INDICE I10 22</b>					
Last publications					
<a href="#">Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma. Giraudet AL, Vinceneux A, Pretet V, Paquet E, Lajusticia AS, Khayi F, Badel JN, Boyle H, Flechon A, Kryza D. Pharmaceuticals (Basel). 2023 Jul 12;16(7):995. doi: 10.3390/ph16070995.PMID: 37513907</a>					
<a href="#">From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors.</a>					

ALG 3/8/2023

Kryza D, Wischhusen J, Richaud M, Hervieu M, Sidi Boumedine J, Delcros JG, Besse S, Baudier T, Laval PA, Breusa S, Boutault E, Clermidy H, Rama N, Ducarouge B, Devouassoux-Shisheboran M, Chezal JM, **Giraudet AL**, Walter T, Mehlen P, Sarrut D, Gibert B. EMBO Mol Med. 2023 Apr 11;15(4):e16732. doi: 10.15252/emmm.202216732. Epub 2023 Mar 6.PMID: 36876343

[Phase III study of 18F-PSMA-1007 versus 18F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, cross-over, multicenter study.](#)

Olivier P, **Giraudet AL**, Skanjeti A, Merlin C, Weinmann P, Rudolph I, Hoepfing A, Gauthé M. J Nucl Med. 2022 Nov 23;jnumed.122.264743. doi: 10.2967/jnumed.122.264743.

[Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer](#)

Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, Do Cao C, Kelly A, Barge ML, Lacroix L, Dygai I, Vera P, Rusu D, Schneegans O, Benisvy D, Klein M, Roux J, Eberle MC, Bastie D, Nascimento C, **Giraudet AL**, Le Moullec N, Bardet S, Drui D, Roudaut N, Godbert Y, Morel O, Drutel A, Lamartina L, Schvartz C, Velayoudom FL, Schlumberger MJ, Leenhardt L, Borget I. N Engl J Med. 2022 Mar 10;386(10):923-932. doi: 10.1056/NEJMoa2111953. PMID: 35263518

[PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?](#)

**Anne-Laure Giraudet**, David Kryza, Michael Hofman, Aurélie Moreau, Karim Fizazi, Aude Flechon, Rodney J Hicks, Ben Tran. Ther Adv Med Oncol. 2021 Oct 26;13:17588359211053898. doi: 10.1177/17588359211053898. eCollection 2021.

[Intense Diffuse Lung Uptake Due to Interstitial Pneumopathy Related to Polyangiitis Granulomata in 68Ga-PSMA-11 PET/CT.](#)

Moreau A, Pretet V, Paquet E, **Giraudet AL**, Kryza D. Clin Nucl Med. 2022 Sep 12. doi: 10.1097/RLU.

[Survey by the French Medicine Agency \(ANSM\) of the imaging protocol, detection rate, and safety of 68 Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18 F-fluorocholine PET/CT: 1084 examinations.](#)

Yanna-Marina Chevalme, Lotfi Boudali, Mathieu Gauthé, Caroline Rousseau, Andrea Skanjeti, Charles Merlin, Philippe Robin, **Anne-Laure Giraudet**, Marc Janier, Jean-Noël Talbot. Eur J Nucl Med Mol Imaging. 2021 Jan 8. doi: 10.1007/s00259-020-05086-1. Online ahead of print. PMID: 33416958 DOI: 10.1007/s00259-020-05086-1

[Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network](#)

Françoise Bonichon, Thierry de Baere, Amandine Berdelou, Sophie Leboulleux, **Anne-Laure Giraudet**, Marie Cuinet, Delphine Drui, Renan Liberge, Antony Kelly, Florence Tenenbaum, Paul Legmann, Christine Do Cao, Laurence Leenhardt, Michel Toubeau, Yann Godbert, Jean Palussière. Among authors: **Giraudet al**. Endocrine 2021 Mar 26. doi: 10.1007/s12020-020-02580-2. Online ahead of print. PMID: 33770383 DOI: 10.1007/s12020-020-02580-2

## NETWORKS :

- Inside the French Society of Nuclear Medicine (SFMN):
  - o Leader of the radioligand therapy French network.
  - o Member of the radioprotection network.
  - o Member of the endocrine network.
  - o Member of the administration committee and the bureau of the (SFMN).
- Member of the TUTHYREF network (French network of iodine refractory thyroid cancer).
- President of the ACOMEN (Action Concertée en Médecine Nucléaire).

## RESEARCH:

- Co-Leader of the IRP3 of the SIRIC in Lyon 2018-2023 LYriCan: Manipulating cell plasticity for innovative cancer treatment.  
IRP3: PHYSICAL AND MATHEMATICAL METHODS TO ANALYZE AND OVERCOME TUMOR PLASTICITY AT THE MACROSCOPIC LEVEL FOR PERSONALIZED TREATMENTS.
- Affiliated to the INSERM research team headed by Nicolas Foray UMR 1296 « Radiations : Défense, Santé, Environnement », Centre Léon Bérard.

## TEACHING RLT:

- to nuclear medicine physicians and physicists at the INSTN (Institut national des sciences et techniques nucléaires), CEA, SACLAY.
- to technicians through the ACOMEN/SFMN (ACORAMEN).

03 Aug 2023

**Docteur Anne-Laure GIRAUDET  
LUMEN**

15 rue Gabriel Sarrazin  
69373 LYON Cedex 08  
N° RPPS 10001547958

• FINESS (GCS/LCU) 69 003 730 4  
Tél. 04 78 78 26 83